[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367731-105":59,"doc-detail-367731-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","case-report-pathological-complete-response-achieved-with-neoadjuvant-immunochemotherapy-in-synchronous-multiple-gastric-adenocarcinoma","Case Report: Pathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma","","Synchronous multiple gastric cancers (SMGC) are a rare condition without established treatment guidelines. A 76-year-old woman with two synchronous poorly differentiated adenocarcinomas (dMMR/MSI-H) was clinically staged as cT4bN2M0. After three cycles of neoadjuvant immunochemotherapy, the patient showed marked tumor regression with RECIST 1.1 partial response, followed by R0 distal gastrectomy. Pathology confirmed a pathological complete response (ypT0N0, TRG 0). The case supports that PD-1 inhibition plus chemotherapy may induce profound regression in SMGC and convert unresectable disease to resectable.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-pathological-complete-response-achieved-with-neoadjuvant-immunochemotherapy-in-synchronous-multiple-gastric-adenocarcinoma/367731/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-pathological-complete-response-achieved-with-neoadjuvant-immunochemotherapy-in-synchronous-multiple-gastric-adenocarcinoma/367731.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the clinical significance of synchronous multiple gastric cancers (SMGC) in this report?","Question",{"text":113,"@type":114},"SMGC is described as a rare clinical entity with no established treatment guidelines, and it may have more aggressive biology and poorer chemotherapy responses than solitary gastric cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What neoadjuvant therapy did the patient receive?",{"text":118,"@type":114},"The patient received three cycles of neoadjuvant therapy with SOX (oxaliplatin plus S-1) combined with tislelizumab (200 mg on day 1) every 3 weeks.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key pathological and clinical outcomes after treatment and surgery?",{"text":122,"@type":114},"After neoadjuvant therapy, imaging showed RECIST 1.1 partial response and the patient subsequently underwent R0 distal gastrectomy. Histopathology confirmed pathological complete response (ypT0N0, TRG 0).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367731,1790307869,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Case Report PUBLISHED 18 July 2025  \nDOI 10.3389/fimmu.2025.1611281  \nOPEN ACCESS  \nEDITED BY  \nStavros P. Papadakos,  \nLaiko General Hospital of Athens, Greece  \nREVIEWED BY  \nYuan Tian,  \nAfﬁliated Hospital of Shandong University of Traditional Chinese Medicine, China Tao Li,  \nPeople’s Liberation Army General Hospital, China  \nHesong Wang,  \nFourth Hospital of Hebei Medical University, China  \n*CORRESPONDENCE  \nXian-Wen Liang  \n [lxwzndx@163.com](lxwzndx@163.com)[ ](lxwzndx@163.com)[Xiong-hui He](Xiong-hui He)  \n [hxh7582@163.com](hxh7582@163.com)[ ](hxh7582@163.com)[Ke-jian Zou](Ke-jian Zou)  \n [zoukejian188@163.com](zoukejian188@163.com)  \n†These authors share ﬁrst authorship  \nRECEIVED 14 April 2025  \nACCEPTED 30 June 2025  \nPUBLISHED 18 July 2025  \nCITATION  \nSun Y-h, Ma Y, Chen L, Li H-r, Liang X-W, He X-h and Zou K-j (2025) Case Report:  \nPathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma.  \nFront. Immunol. 16:1611281 .  \ndoi: 10.3389/fimmu.2025.1611281  \nCOPYRIGHT  \n© 2025 Sun, Ma, Chen, Li, Liang, He and Zou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase Report: Pathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma  \nYa-hui Sun 1†, Yan Ma 1†, Liang Chen 2, Hai-rong Li 3, Xian-Wen Liang 1*, Xiong-hui He 1* and Ke-jian Zou 1*  \n1 Department of Gastrointestinal Surgery, Hainan General Hospital (Hainan Afﬁliated Hospital of Hainan Medical University), Haikou, China, 2 Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital (Hainan Afﬁliated Hospital of Hainan Medical University), Haikou, China, 3 Department of Pathology, Hainan General Hospital (Hainan Afﬁliated Hospital of Hainan Medical University), Haikou, China  \nSynchronous multiple gastric cancers (SMGC) represent a rare clinical entity with no established treatment guidelines. We report a 76-year-old female with two synchronous poorly differentiated adenocarcinomas (dMMR/MSI-H phenotype) in the gastric lesser curvature, clinically staged as cT4bN2M0 . Following three cycles of neoadjuvant immunochemotherapy, the patient demonstrated remarkable tumor regression (RECIST 1.1 partial response) and subsequently underwent R0 distal gastrectomy. Histopathological examination conﬁrmed a pathological complete response (ypT0N0, TRG 0) .To our knowledge, this represents the ﬁrst documented case of SMGC achieving pCR with neoadjuvant immunochemotherapy. Our ﬁndings suggest that PD-1 inhibition combined with chemotherapy may induce profound tumor regression in SMGC, even in cases with high tumor burden, potentially converting unresectable toresectable disease. This case provides compelling evidence for incorporating immunotherapy in SMGC management and warrants further investigation through clinical trials.  \nKEYWORDS  \nSMGC, neoadjuvant immunochemotherapy, pathological complete response, immune checkpoint inhibitors, microsatellite instability  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nBackground  \nSynchronous multiple gastric cancer (SMGC), deﬁned as ≥2 distinct primary gastric malignancies occurring simultaneously (1), accounting for 6%–14% of all gastric cancer cases (2) . The pathogenesis involves complex interactions between ﬁeldcancerization, tumor microenvironment heterogeneity, and genetic predisposition (3–5) . Current treatment paradigms extrapolate from solitary gastric cancer protocols, despite evidence suggesting SMGC exhibits more aggressive biology and poorer chemotherapy","cbCaiiZ8u4Y7Bu6E","https://ap.wps.com/l/cbCaiiZ8u4Y7Bu6E","pdf",7196447,"English","# Background\n# Case presentation\n## Diagnostic evaluation\n# Diagnostic evaluation\n## Endoscopy\n## Histopathology\n## Radiological staging (CT)\n# Multidisciplinary decision-making\n# Treatment and outcomes","[{\"question\":\"What is the clinical significance of synchronous multiple gastric cancers (SMGC) in this report?\",\"answer\":\"SMGC is described as a rare clinical entity with no established treatment guidelines, and it may have more aggressive biology and poorer chemotherapy responses than solitary gastric cancer.\"},{\"question\":\"What neoadjuvant therapy did the patient receive?\",\"answer\":\"The patient received three cycles of neoadjuvant therapy with SOX (oxaliplatin plus S-1) combined with tislelizumab (200 mg on day 1) every 3 weeks.\"},{\"question\":\"What were the key pathological and clinical outcomes after treatment and surgery?\",\"answer\":\"After neoadjuvant therapy, imaging showed RECIST 1.1 partial response and the patient subsequently underwent R0 distal gastrectomy. Histopathology confirmed pathological complete response (ypT0N0, TRG 0).\"}]","Case Report: Pathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma | PDF",1790172300,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ca986967e8068d0b82b1eddd0bb3a25.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c45c72f321b2d5e508dd53ff7c34d45.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26a2d925aee19c71fcfb9a7fe6f742df.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16110f8baeeda6d8172bf7519bbe1dce.webp",980,1385]